Literature DB >> 25354684

High cerebrospinal fluid levels of interleukin-10 attained by AAV in dogs.

J Pleticha1, S A Malkmus2, L F Heilmann1, S L Veesart2, R Rezek1, Q Xu2, T L Yaksh2, A S Beutler1.   

Abstract

Intrathecal (IT) gene transfer using adeno-associated virus (AAV) may be clinically promising as a treatment for chronic pain if it can produce sufficiently high levels of a transgene product in the cerebrospinal fluid (CSF). Although this strategy was developed in rodents, no studies investigating CSF levels of an analgesic or antiallodynic protein delivered by IT AAV have been performed in large animals. Interleukin-10 (IL-10) is an antiallodynic cytokine for which target therapeutic levels have been established in rats. The present study tested IT AAV8 encoding either human IL-10 (hIL-10) or enhanced green fluorescent protein (EGFP) in a dog model of IT drug delivery. AAV8/hIL-10 at a dose of 3.5 × 10(12) genome copies induced high hIL-10 levels in the CSF, exceeding the target concentration previously found to be antiallodynic in rodents by >1000-fold. AAV8/EGFP targeted the primary sensory and motor neurons and the meninges. hIL-10, a xenogeneic protein in dogs, induced anti-hIL-10 antibodies detectable in the CSF and serum of dogs. The high hIL-10 levels demonstrate the efficacy of AAV for delivery of secreted transgenes into the IT space of large animals, suggesting a strong case for further development toward clinical testing.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25354684      PMCID: PMC5079622          DOI: 10.1038/gt.2014.96

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  45 in total

1.  Herpes simplex virus vector-mediated expression of interleukin-10 reduces below-level central neuropathic pain after spinal cord injury.

Authors:  Darryl Lau; Steven E Harte; Thomas J Morrow; Shiyong Wang; Marina Mata; David J Fink
Journal:  Neurorehabil Neural Repair       Date:  2012-05-15       Impact factor: 3.919

Review 2.  Afferent and efferent immunological pathways of the brain. Anatomy, function and failure.

Authors:  R O Carare; C A Hawkes; R O Weller
Journal:  Brain Behav Immun       Date:  2013-10-18       Impact factor: 7.217

3.  Intrathecal substance P-saporin in the dog: distribution, safety, and spinal neurokinin-1 receptor ablation.

Authors:  Ashley J Wiese; Michael Rathbun; Mark T Butt; Shelle A Malkmus; Philip J Richter; Kent G Osborn; Qinghao Xu; Samantha L Veesart; Joanne J Steinauer; Denise Higgins; Douglas A Lappi; Brian Russell; Tony L Yaksh
Journal:  Anesthesiology       Date:  2013-11       Impact factor: 7.892

4.  Controlling pathological pain by adenovirally driven spinal production of the anti-inflammatory cytokine, interleukin-10.

Authors:  Erin D Milligan; Stephen J Langer; Evan M Sloane; Lin He; Julie Wieseler-Frank; Kevin O'Connor; David Martin; John R Forsayeth; Steven F Maier; Kirk Johnson; Raymond A Chavez; Leslie A Leinwand; Linda R Watkins
Journal:  Eur J Neurosci       Date:  2005-04       Impact factor: 3.386

5.  Cytokine involvement in dynorphin-induced allodynia.

Authors:  T M Laughlin; J R Bethea; R P Yezierski; G L Wilcox
Journal:  Pain       Date:  2000-02       Impact factor: 6.961

6.  Long-term safety and efficacy following systemic administration of a self-complementary AAV vector encoding human FIX pseudotyped with serotype 5 and 8 capsid proteins.

Authors:  Amit C Nathwani; Cecilia Rosales; Jenny McIntosh; Ghasem Rastegarlari; Devhrut Nathwani; Deepak Raj; Sushmita Nawathe; Simon N Waddington; Roderick Bronson; Scott Jackson; Robert E Donahue; Katherine A High; Federico Mingozzi; Catherine Y C Ng; Junfang Zhou; Yunyu Spence; M Beth McCarville; Marc Valentine; James Allay; John Coleman; Susan Sleep; John T Gray; Arthur W Nienhuis; Andrew M Davidoff
Journal:  Mol Ther       Date:  2011-01-18       Impact factor: 11.454

7.  Immunogenicity of enhanced green fluorescent protein (EGFP) in BALB/c mice: identification of an H2-Kd-restricted CTL epitope.

Authors:  A Gambotto; G Dworacki; V Cicinnati; T Kenniston; J Steitz; T Tüting; P D Robbins; A B DeLeo
Journal:  Gene Ther       Date:  2000-12       Impact factor: 5.250

8.  Snake venom phospholipase A2s (Asp49 and Lys49) induce mechanical allodynia upon peri-sciatic administration: involvement of spinal cord glia, proinflammatory cytokines and nitric oxide.

Authors:  Marucia Chacur; Erin D Milligan; Evan M Sloan; Julie Wieseler-Frank; Ruth M Barrientos; David Martin; Stephen Poole; Brono Lomonte; Jose Maria Gutiérrez; Steven F Maier; Yara Cury; Linda R Watkins
Journal:  Pain       Date:  2004-03       Impact factor: 6.961

9.  Whole body correction of mucopolysaccharidosis IIIA by intracerebrospinal fluid gene therapy.

Authors:  Virginia Haurigot; Sara Marcó; Albert Ribera; Miguel Garcia; Albert Ruzo; Pilar Villacampa; Eduard Ayuso; Sònia Añor; Anna Andaluz; Mercedes Pineda; Gemma García-Fructuoso; Maria Molas; Luca Maggioni; Sergio Muñoz; Sandra Motas; Jesús Ruberte; Federico Mingozzi; Martí Pumarola; Fatima Bosch
Journal:  J Clin Invest       Date:  2013-07-01       Impact factor: 14.808

10.  Interleukin-10 as a CNS therapeutic: the obstacle of the blood-brain/blood-spinal cord barrier.

Authors:  Abba J Kastin; Victoria Akerstrom; Weihong Pan
Journal:  Brain Res Mol Brain Res       Date:  2003-06-10
View more
  7 in total

1.  Human interleukin-10 delivered intrathecally by self-complementary adeno-associated virus 8 induces xenogeneic transgene immunity without clinical neurotoxicity in swine.

Authors:  Mark D Unger; Josef Pleticha; Lukas F Heilmann; Laura K Newman; Timothy P Maus; Andreas S Beutler
Journal:  J Gene Med       Date:  2018-06-15       Impact factor: 4.565

2.  Fatal Meningitis in Swine after Intrathecal Administration of Adeno-associated Virus Expressing Syngeneic Interleukin-10.

Authors:  Mark D Unger; Josef Pleticha; James E Collins; Anibal G Armien; Jennifer L Brazzell; Laura K Newman; Lukas F Heilmann; Jodi A Scholz; Timothy P Maus; Andreas S Beutler
Journal:  Mol Ther       Date:  2017-08-01       Impact factor: 11.454

Review 3.  Targeting dorsal root ganglia and primary sensory neurons for the treatment of chronic pain.

Authors:  Temugin Berta; Yawar Qadri; Ping-Heng Tan; Ru-Rong Ji
Journal:  Expert Opin Ther Targets       Date:  2017-05-16       Impact factor: 6.902

Review 4.  Current and Future Issues in the Development of Spinal Agents for the Management of Pain.

Authors:  Tony L Yaksh; Casey J Fisher; Tyler M Hockman; Ashley J Wiese
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

5.  Inhibition of neuropathic hyperalgesia by intrathecal bone marrow stromal cells is associated with alteration of multiple soluble factors in cerebrospinal fluid.

Authors:  Gregory Fischer; Fei Wang; Hongfei Xiang; Xiaowen Bai; Hongwei Yu; Quinn H Hogan
Journal:  Exp Brain Res       Date:  2017-06-01       Impact factor: 1.972

Review 6.  Current gene therapy using viral vectors for chronic pain.

Authors:  Jean-Marc G Guedon; Shaogen Wu; Xuexing Zheng; Caroline C Churchill; Joseph C Glorioso; Ching-Hang Liu; Shue Liu; Lucy Vulchanova; Alex Bekker; Yuan-Xiang Tao; Paul R Kinchington; William F Goins; Carolyn A Fairbanks; Shuanglin Hao
Journal:  Mol Pain       Date:  2015-05-13       Impact factor: 3.395

Review 7.  The search for novel analgesics: targets and mechanisms.

Authors:  Tony L Yaksh; Sarah A Woller; Roshni Ramachandran; Linda S Sorkin
Journal:  F1000Prime Rep       Date:  2015-05-26
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.